Payment overview · 2025
General Payments
$976.27
89 reported records · 14 companies
Healthcare provider profile · identity verified
Jarrett Hammer, DO
Allopathic & Osteopathic Physicians|Family Medicine · SALEM, UT · NPI 1417152026
Verified facts
What the public records show
CMS Open Payments records show Jarrett Hammer, DO received $976.27 in general payments during 2025 across 89 reported records.
ABBVIE INC. accounted for 43.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $420.84 | 43.1% | 27 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $146.04 | 15.0% | 38 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $65.87 | 6.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.02 | 6.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.40 | 5.7% | 3 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $55.29 | 5.7% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $33.25 | 3.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.67 | 2.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $24.11 | 2.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.37 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.48 | 1.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.24 | 1.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.60 | 1.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.09 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $976.27 | 89 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $224.75 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $206.41 | 13 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $156.71 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $108.10 | 35 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $108.10 | 35 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $65.87 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $59.02 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $59.02 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $55.40 | 3 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $55.29 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.94 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $33.25 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.67 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.67 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.12 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| LILETTA Normalized: liletta |
Drug | ABBVIE INC. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 102 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 474 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 322 | 93 |
| Omeprazole | Omeprazole | 260 | 74 |
| Gabapentin | Gabapentin | 200 | 40 |
| Losartan Potassium | Losartan Potassium | 188 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 175 | 46 |
| Lisinopril | Lisinopril | 158 | 46 |
| Metformin Hcl | Metformin Hcl | 151 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 43 |
| Trazodone Hcl | Trazodone Hcl | 119 | 31 |
| Celecoxib | Celecoxib | 115 | 31 |
| Jardiance | Empagliflozin | 102 | 19 |
| Tramadol Hcl | Tramadol Hcl | 100 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 32 |
| Simvastatin | Simvastatin | 88 | 28 |
| Metformin Hcl Er | Metformin Hcl | 87 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 16 |
| Pregabalin | Pregabalin | 83 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 21 |
| Meloxicam | Meloxicam | 76 | 21 |
| Potassium Chloride | Potassium Chloride | 75 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 71 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 18 |
| Montelukast Sodium | Montelukast Sodium | 70 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 26 |
| Allopurinol | Allopurinol | 67 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 23 |
| Clonazepam | Clonazepam | 66 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 12 |
| Sertraline Hcl | Sertraline Hcl | 55 | suppressed |
| Eliquis | Apixaban | 54 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 54 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 12 |
| Carvedilol | Carvedilol | 49 | 13 |
| Buspirone Hcl | Buspirone Hcl | 48 | 11 |
| Famotidine | Famotidine | 48 | 14 |
| Ozempic | Semaglutide | 48 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | 11 |
| Ibuprofen | Ibuprofen | 45 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | suppressed |
| Spironolactone | Spironolactone | 45 | 11 |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Furosemide | Furosemide | 44 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 15 |
| Alendronate Sodium | Alendronate Sodium | 43 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | suppressed |
| Temazepam | Temazepam | 39 | suppressed |
| Baclofen | Baclofen | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | 11 |
| Methocarbamol | Methocarbamol | 38 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Estradiol | Estradiol | 34 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 15 |
| Prednisone | Prednisone | 32 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 27 | 19 |
| Nystatin | Nystatin | 27 | 14 |
| Alprazolam | Alprazolam | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Progesterone | Progesterone, Micronized | 18 | suppressed |
| Silodosin | Silodosin | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Effexor Xr | Venlafaxine Hcl | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $976.27 · 89 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, CAPLYTA, CAPVAXIVE, COMIRNATY, GARDASIL 9, INSPIRE, JARDIANCE, LILETTA, MOUNJARO, NEXPLANON, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, ROTATEQ, TZIELD, UBRELVY, VAXELIS, VAXNEUVANCE, VRAYLAR, Veozah, WaveWriter Alpha Prime 16, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error